Niu Dong-Guang, Huang Qian, Yang Fan, Tian Wei-Liang, Zhao Yun-Zhao
Department of General Surgery, Jinling Clinical College of Nanjing Medical University, Nanjing, China.
J Laparoendosc Adv Surg Tech A. 2019 Jul;29(7):905-908. doi: 10.1089/lap.2018.0792. Epub 2019 Mar 15.
Coupled plasma filtration adsorption (CPFA) is an extracorporeal treatment based on plasma filtration associated with an adsorbent cartridge and hemofiltration. CPFA is able to remove inflammatory mediators and it has been used to treat severe sepsis and multiple organ dysfunction. Limited experience exists on the use of CPFA in treating intra-abdominal infection (IAI). In this study, the efficacy of CPFA in treating patients with severe IAI and liver failure was evaluated in a retrospective analysis of 76 cases. The survival rate of patients treated with CPFA was 82.6%, with effective removal of endotoxin and inflammatory mediators. Our data suggest that CPFA can be safely and effectively used to lower morbidity and mortality rates of patients with severe IAI and liver failure.
配对血浆滤过吸附（CPFA）是一种基于血浆滤过并与吸附柱及血液滤过相关联的体外治疗方法。CPFA能够清除炎症介质，已被用于治疗严重脓毒症和多器官功能障碍。关于CPFA用于治疗腹腔内感染（IAI）的经验有限。在本研究中，通过对76例病例的回顾性分析评估了CPFA治疗严重IAI和肝功能衰竭患者的疗效。接受CPFA治疗的患者生存率为82.6%，内毒素和炎症介质得到有效清除。我们的数据表明，CPFA可安全有效地用于降低严重IAI和肝功能衰竭患者的发病率和死亡率。
